Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States [Corrigendum]

Sendzischew Shane MA, Ruddy J, Cline M, Rosenbaum DP, Edelstein S, Moshiree B. Clin Exp Gastroenterol. 2024;17:227—253. The authors have advised of errors in Figure 2 on page 234. Under the US FDA-approved prescription medications, Chloride channel agonists subsection is incorrect. A new subsection “Guanylate cyclase agonists” should be included and “Lifestyle interventions” should read “Linaclotide”. The correct Figure 2 is presented as follows. Figure 2 Treatment recommendations for IBS-C according to current US guidelines.1,62,63 Note that although tegaserod is included in the guidelines, it has been omitted from this figure as it has been withdrawn from the market and is unavailable for prescription. aLifestyle modification suggested by the AGA: exercise, sleep, stress reduction. bAt the time of preparation of the most recent ACG guidelines, the amount of real-world clinical practice experience with tenapanor available for consideration by the ACG would have been limited (tenapanor received FDA approval for use in 2019).Abbreviations: ACG, indicates American College of Gastroenterology; AGA, American Gastroenterological Association; CBT, cognitive behavioral therapy; FDA, Food and Drug Administration; FODMAP, fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; IBS, irritable bowel syndrome; OTC, over-the-counter; PEG, polyethylene glycol; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; US, United States. The authors apologize for this error.